Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer . . . Introduction Treatment of metastatic castrate-sensitive prostate cancer (mCSPC) has evolved dramatically over the past 20 years In the early 21st century, treatment of advanced prostate cancer relied upon androgen ablation via either surgical castration or neutralization through estrogen administration 1, 2 Increased understanding of the androgen pathways led to the development of new means
Real-world insights into treating metastatic castration-sensitive . . . A group of urologists from across the Dallas region convened for a recent Urology Times Clinical Forum moderated by Matthew L Wilner, MD, of Urology Clinics of North Texas to discuss evolving approaches to managing metastatic castration-sensitive prostate cancer (mCSPC) The discussion focused on treatment selection, sequencing of therapies, and real-world factors affecting adoption of
Treating metastatic castration-sensitive prostate cancer | Urology A group of urologists from across the Dallas region convened for a recent Urology Times Clinical Forum moderated by Matthew L Wilner, MD, of Urology Clinics of North Texas to discuss evolving approaches to managing metastatic castration-sensitive prostate cancer (mCSPC) The discussion focused on treatment selection, sequencing of therapies, and real-world factors affecting adoption of
How We Treat Metastatic Castration-Sensitive Prostate Cancer Risk Stratifying Metastatic Castration-Sensitive Prostate Cancer Among the numerous available strategies, the best choice of first-line therapy for mCSPC is a contentious matter, primarily due to the remarkably variable clinical course of this disease state
Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient . . . Prostate cancer accounts for one in every five cancer diagnoses, making it the most common cancer in men, and metastatic prostate cancer is the second most common cause of cancer-related deaths in men in the United States 1 The incidence of prostate cancer began to decline in 2000, and it has more rapidly declined since the U S Preventive
Treatment for Metastatic Prostate Cancer Often Suboptimal In most people with metastatic hormone-sensitive prostate cancer, the cancer eventually changes so that it can grow without being reliant on testosterone from the testes, known as hormone-resistant (or castration-resistant) disease
日历月历